Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: April K.S. Salama, Shuli Li, Erin Renee Macrae, Jong-In Park, Edith P. Mitchell, James A. Zwiebel, Helen X. Chen, Robert James Gray, Lisa McShane, Lawrence Rubinstein, David Patton, Paul M. Williams, Stanley R. Hamilton, Deborah Kay Armstrong, Barbara A. Conley, Carlos L. Arteaga, Lyndsay Harris, Peter J. O'Dwyer, Alice P. Chen, Keith Flaherty
Institutions: Duke University, Columbus Oncology and Hematology Associates, Medical College of Wisconsin, Thomas Jefferson University, Thomas Jefferson University Hospital, National Cancer Institute, Dana-Farber Cancer Institute, Frederick National Laboratory for Cancer Research, The University of Texas MD Anderson Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, National Institutes of Health, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Abramson Cancer Center, Harvard University, Massachusetts General Hospital
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2947233266